Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.
Misoprostol effectively prevents nonsteroidal anti-inflammatory drugs (NSAID)-induced gastric ulcer and is the only agent currently indicated for this purpose.  In addition, misoprostol is effective as prophylaxis against NSAID-induced duodenal ulcer.  Because of the widespread use of NSAIDs, the cost of routine misoprostol prophylaxis would be high, and thus its pharmacoeconomic evaluation is an important factor in assessing the most appropriate role of misoprostol in this group of patients.  Current cost-benefit analyses undertaken in major European centres and the US have generally indicated that, depending on initial assumptions, misoprostol prophylaxis over a 3-month period is cost-saving in patients with osteoarthritis taking NSAIDs.  The net savings (costs) realised were dependent on several variables, including the acquisition cost of misoprostol, silent ulcer rate and patients' compliance.  Importantly, misoprostol prophylaxis was consistently more cost-beneficial in elderly patients aged greater than 60 to 65 years than in their younger counterparts.  In contrast, in one study misoprostol was found to reduce patients' quality of life and, although misoprostol therapy is potentially cost-saving to society, patients generally preferred no therapy.  A single study assessing the cost-effectiveness of misoprostol prophylaxis in preventing ulcerative complications concluded that primary treatment was not an economically viable option for all NSAID users.  Misoprostol was most cost-effective in the prevention of recurrent or secondary gastric ulcer complications in 'high-risk' patients, for example patients aged over 60 years and patients with rheumatoid arthritis.  Thus, although there are areas of interest awaiting further pharmacoeconomic investigation, misoprostol prophylaxis appears to be cost-effective in elderly and high risk patients receiving NSAIDs.  Additionally, misoprostol prophylaxis is cost-saving in elderly patients with osteoarthritis requiring NSAID therapy.
Barradell
L B
LB
Adis International Limited, Auckland, New Zealand.
Whittington
R
R
Benfield
P
P
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D003663:Decision Trees; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D017850:Economics, Pharmaceutical / Q000639:trends; D005544:Forecasting; D005753:Gastric Mucosa / Q000293:injuries / Q000503:physiopathology; D006760:Hospitalization; D006801:Humans; D016595:Misoprostol / Q000191:economics / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome